Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation

Masuho Saburi, Sumiko Kohashi, Jun Kato, Yuya Koda, Masatoshi Sakurai, Takaaki Toyama, Taku Kikuchi, Daiki Karigane, Sayako Yuda, Yusuke Yamane, Risa Hashida, Ryohei Abe, Tomonori Nakazato, Junichi Hirahashi, Masao Ogata, Shinichiro Okamoto, Takehiko Mori

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalInternational Journal of Hematology
DOIs
Publication statusAccepted/In press - 2017 May 17

Fingerprint

Hematopoietic Stem Cell Transplantation
Tacrolimus
Cyclosporine
Sodium
Transplantation
Hyperuricemia
Hyperkalemia
Calcineurin Inhibitors
Creatinine
Tissue Donors
Kidney
Serum

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Calcineurin inhibitor
  • Cyclosporine A
  • Sodium excretion
  • Tacrolimus

ASJC Scopus subject areas

  • Hematology

Cite this

Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation. / Saburi, Masuho; Kohashi, Sumiko; Kato, Jun; Koda, Yuya; Sakurai, Masatoshi; Toyama, Takaaki; Kikuchi, Taku; Karigane, Daiki; Yuda, Sayako; Yamane, Yusuke; Hashida, Risa; Abe, Ryohei; Nakazato, Tomonori; Hirahashi, Junichi; Ogata, Masao; Okamoto, Shinichiro; Mori, Takehiko.

In: International Journal of Hematology, 17.05.2017, p. 1-5.

Research output: Contribution to journalArticle

@article{4aa065f67cbb4d599d35d50c125a9b2e,
title = "Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation",
abstract = "Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Calcineurin inhibitor, Cyclosporine A, Sodium excretion, Tacrolimus",
author = "Masuho Saburi and Sumiko Kohashi and Jun Kato and Yuya Koda and Masatoshi Sakurai and Takaaki Toyama and Taku Kikuchi and Daiki Karigane and Sayako Yuda and Yusuke Yamane and Risa Hashida and Ryohei Abe and Tomonori Nakazato and Junichi Hirahashi and Masao Ogata and Shinichiro Okamoto and Takehiko Mori",
year = "2017",
month = "5",
day = "17",
doi = "10.1007/s12185-017-2253-x",
language = "English",
pages = "1--5",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation

AU - Saburi, Masuho

AU - Kohashi, Sumiko

AU - Kato, Jun

AU - Koda, Yuya

AU - Sakurai, Masatoshi

AU - Toyama, Takaaki

AU - Kikuchi, Taku

AU - Karigane, Daiki

AU - Yuda, Sayako

AU - Yamane, Yusuke

AU - Hashida, Risa

AU - Abe, Ryohei

AU - Nakazato, Tomonori

AU - Hirahashi, Junichi

AU - Ogata, Masao

AU - Okamoto, Shinichiro

AU - Mori, Takehiko

PY - 2017/5/17

Y1 - 2017/5/17

N2 - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.

AB - Calcineurin inhibitors (CIs) such as cyclosporine A (CSA) and tacrolimus often cause renal dysfunction, resulting in increased serum creatinine, hyperkalemia, and hyperuricemia. However, the effects of CIs on sodium excretion have not been fully elucidated. We retrospectively evaluated the effects of CI administration on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation (HSCT). Fifty consecutive recipients each of allogeneic HSCT receiving either CSA or tacrolimus (100 patients in total) with available data for weekly fractional excretion of sodium (FENa) for a 4-week period after transplantation were enrolled in this retrospective analysis. No significant differences in patient characteristics were observed between CSA and tacrolimus groups except for the type of donor. FENa was significantly higher at the 3rd (1.25 ± 0.80) and 4th weeks (1.53 ± 1.06) after transplantation as compared with that at the 1st week (0.93 ± 0.51; P < 0.01, P < 0.001, respectively) in the tacrolimus group, but not at any time point in the CSA group. In addition, FENa was significantly higher in the tacrolimus group than the CSA group at the 4th week (1.53 ± 1.06 vs. 1.13 ± 0.80; P < 0.05). These results suggest that tacrolimus increases sodium excretion after allogeneic HSCT, and that this effect is minimal with CSA.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Calcineurin inhibitor

KW - Cyclosporine A

KW - Sodium excretion

KW - Tacrolimus

UR - http://www.scopus.com/inward/record.url?scp=85019634231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019634231&partnerID=8YFLogxK

U2 - 10.1007/s12185-017-2253-x

DO - 10.1007/s12185-017-2253-x

M3 - Article

C2 - 28516402

AN - SCOPUS:85019634231

SP - 1

EP - 5

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -